{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:44:47Z","timestamp":1788918287669,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T00:00:00Z","timestamp":1481587200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T00:00:00Z","timestamp":1481587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001863","name":"New Energy and Industrial Technology Development Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001863","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"crossref"}]},{"name":"J-ADNI Pharmaceutical Industry Scientific Advisory Board Companies"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s00259-016-3591-2","type":"journal-article","created":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T02:14:09Z","timestamp":1481595249000},"page":"850-857","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":120,"title":["Inter-rater variability of visual interpretation and comparison with quantitative evaluation of 11C-PiB PET amyloid images of the Japanese Alzheimer\u2019s Disease Neuroimaging Initiative (J-ADNI) multicenter study"],"prefix":"10.1007","volume":"44","author":[{"name":"J-ADNI Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0955-4272","authenticated-orcid":false,"given":"Tomohiko","family":"Yamane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneyuki","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Ikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Senda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,13]]},"reference":[{"key":"3591_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"3591_CR2","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/nrd3505","volume":"10","author":"E Karran","year":"2011","unstructured":"Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer\u2019s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10:698\u2013712.","journal-title":"Nat Rev Drug Discov"},{"key":"3591_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack Jr","year":"2010","unstructured":"Jack Jr CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol. 2010;9:119\u201328. doi:\n                    10.1016\/S474-4422(09)70299-6\n                    \n                  .","journal-title":"Lancet Neurol"},{"key":"3591_CR4","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"W Klunk","year":"2004","unstructured":"Klunk W, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt D, et al. Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306\u201319.","journal-title":"Ann Neurol"},{"key":"3591_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous Sr MD, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1\u201315.","journal-title":"Alzheimers Dement"},{"key":"3591_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40336-015-0102-6","volume":"3","author":"O Sabri","year":"2015","unstructured":"Sabri O, Seibyl J, Rowe C, Barthel H. Beta-amyloid imaging with florbetaben. Clin Transl Imaging. 2015;3:13\u201326.","journal-title":"Clin Transl Imaging"},{"key":"3591_CR7","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","volume":"72","author":"C Curtis","year":"2015","unstructured":"Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72:287\u201394.","journal-title":"JAMA Neurol"},{"key":"3591_CR8","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMp1208061","volume":"367","author":"L Yang","year":"2012","unstructured":"Yang L, Rieves D, Ganley C. Brain amyloid imaging\u2014FDA approval of florbetapir F18 injection. N Engl J Med. 2012;367:885\u20137. doi:\n                    10.1056\/NEJMp1208061\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"3591_CR9","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s00259-013-2564-y","volume":"41","author":"S Hatashita","year":"2014","unstructured":"Hatashita S, Yamasaki H, Suzuki Y, Tanaka K, Wakebe D, Hayakawa H. [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2014;41:290\u2013300.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3591_CR10","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1212\/WNL.0b013e31823b9c5e","volume":"77","author":"G Rabinovici","year":"2011","unstructured":"Rabinovici G, Rosen H, Alkalay A, Kornak J, Furst A, Agarwal N, et al. Amyloid vs. FDG-PET in the differential diagnosis of AD and FTLD. Neurology. 2011;77:2034\u201342.","journal-title":"Neurology"},{"key":"3591_CR11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2967\/jnumed.106.037762","volume":"48","author":"S Ng","year":"2007","unstructured":"Ng S, Villemagne VL, Berlangieri S, Lee ST, Cherk M, Gong SJ, et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer\u2019s disease. J Nucl Med. 2007;48:547\u201352.","journal-title":"J Nucl Med"},{"key":"3591_CR12","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.neuroimage.2010.12.070","volume":"55","author":"BL Rosario","year":"2011","unstructured":"Rosario BL, Weissfeld LA, Laymon CM, Mathis CA, Klunk WE, Berginc MD, et al. Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET. Neuroimage. 2011;55:933\u201341.","journal-title":"Neuroimage"},{"key":"3591_CR13","doi-asserted-by":"publisher","first-page":"5768","DOI":"10.1088\/0031-9155\/61\/15\/5768","volume":"61","author":"G Akamatsu","year":"2016","unstructured":"Akamatsu G, Ikari Y, Ohnishi A, Nishida H, Aita K, Sasaki M, et al. Automated PET-only quantification of amyloid deposition with adaptive template and empirically pre-defined ROI. Phys Med Biol. 2016;61:5768\u201380.","journal-title":"Phys Med Biol"},{"key":"3591_CR14","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00259-010-1382-8","volume":"37","author":"T Suotunen","year":"2010","unstructured":"Suotunen T, Hirvonen J, Immonen-Raiha P, Aalto S, Lisinen I, Arponen E, et al. Visual assessment of [(11)C]PIB PET in patients with cognitive impairment. Eur J Nucl Med Mol Imaging. 2010;37:1141\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3591_CR15","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1136\/jnnp.2009.194779","volume":"81","author":"N Tolboom","year":"2010","unstructured":"Tolboom N, van der Flier WM, Boverhoff J, Yaqub M, Wattjes MP, Raijmakers PG, et al. Molecular imaging in the diagnosis of Alzheimer\u2019s disease: visual assessment of [11C]PIB and [18F]FDDNP PET images. J Neurol Neurosurg Psychiatry. 2010;81:882\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3591_CR16","doi-asserted-by":"publisher","first-page":"900","DOI":"10.2967\/jnumed.115.161927","volume":"57","author":"J Seibyl","year":"2016","unstructured":"Seibyl J, Catafau AM, Barthel H, Ishii K, Rowe CC, Leverenz JB, et al. Impact of training method on the robustness of the visual assessment of 18F-Florbetaben PET scans: results from a phase-3 study. J Nucl Med. 2016;57:900\u20136.","journal-title":"J Nucl Med"},{"key":"3591_CR17","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3174\/ajnr.A4281","volume":"36","author":"AP Nayate","year":"2015","unstructured":"Nayate AP, Dubroff JG, Schmitt JE, Nasrallah I, Kishore R, Mankoff D, et al. Use of standardized uptake value ratios decreases interreader variability of [18F] Florbetapir PET brain scan interpretation. AJNR Am J Neuroradiol. 2015;36:1237\u201344.","journal-title":"AJNR Am J Neuroradiol"},{"key":"3591_CR18","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3174\/ajnr.A3665","volume":"35","author":"T Yamane","year":"2014","unstructured":"Yamane T, Ikari Y, Nishio T, Ishii K, Ishii K, Kato T, et al. Visual-statistical interpretation of (18)F-FDG-PET images for characteristic Alzheimer patterns in a multicenter study: inter-rater concordance and relationship to automated quantitative evaluation. AJNR Am J Neuroradiol. 2014;35:244\u20139.","journal-title":"AJNR Am J Neuroradiol"},{"key":"3591_CR19","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","volume":"11","author":"CM Clark","year":"2012","unstructured":"Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: a prospective cohort study. Lancet Neurol. 2012;11:669\u201378.","journal-title":"Lancet Neurol"},{"key":"3591_CR20","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1212\/WNL.0b013e3181c679cc","volume":"73","author":"N Tolboom","year":"2009","unstructured":"Tolboom N, van der Flier WM, Yaqub M, Koene T, Boellaard R, Windhorst AD, et al. Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment. Neurology. 2009;73:2079\u201385.","journal-title":"Neurology"},{"key":"3591_CR21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2967\/jnumed.115.163717","volume":"57","author":"T Grimmer","year":"2016","unstructured":"Grimmer T, Wutz C, Alexopoulos P, Drzezga A, Forster S, Forstl H, et al. Visual versus fully automated analyses of 18F-FDG and Amyloid PET for prediction of dementia due to Alzheimer disease in mild cognitive impairment. J Nucl Med. 2016;57:204\u20137.","journal-title":"J Nucl Med"},{"key":"3591_CR22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jalz.2010.03.011","volume":"6","author":"T Iwatsubo","year":"2010","unstructured":"Iwatsubo T. Japanese Alzheimer\u2019s disease neuroimaging initiative: present status and future. Alzheimers Dement. 2010;6:297\u20139.","journal-title":"Alzheimers Dement"},{"key":"3591_CR23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s12149-012-0605-4","volume":"26","author":"Y Ikari","year":"2012","unstructured":"Ikari Y, Nishio T, Makishi Y, Miya Y, Ito K, Koeppe RA, et al. Head motion evaluation and correction for PET scans with 18F-FDG in the Japanese Alzheimer\u2019s disease neuroimaging initiative (J-ADNI) multi-center study. Ann Nucl Med. 2012;26:535\u201344.","journal-title":"Ann Nucl Med"},{"key":"3591_CR24","unstructured":"Japanese Alzheimer\u2019s disease neuroimaging initiative (J-ADNI) (NBDC Research ID: hum0043.v1). National Bioscience Database Center website. \n                    http:\/\/humandbs.biosciencedbc.jp\/en\/hum0043-v1\n                    \n                  ."},{"key":"3591_CR25","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology. 1984;34:939\u201344.","journal-title":"Neurology"},{"key":"3591_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0197-4580(97)00056-0","volume":"18","author":"H Braak","year":"1997","unstructured":"Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351\u20137.","journal-title":"Neurobiol Aging"},{"key":"3591_CR27","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1212\/WNL.52.6.1158","volume":"52","author":"A Delacourte","year":"1999","unstructured":"Delacourte A, David JP, Sergeant N, Buee L, Wattez A, Vermersch P, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer\u2019s disease. Neurology. 1999;52:1158\u201365.","journal-title":"Neurology"},{"key":"3591_CR28","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.2967\/jnumed.114.142109","volume":"55","author":"L Thurfjell","year":"2014","unstructured":"Thurfjell L, Lilja J, Lundqvist R, Buckley C, Smith A, Vandenberghe R, et al. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads. J Nucl Med. 2014;55:1623\u20138.","journal-title":"J Nucl Med"},{"key":"3591_CR29","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1001\/jamaneurol.2015.1633","volume":"72","author":"S Schreiber","year":"2015","unstructured":"Schreiber S, Landau SM, Fero A, Schreiber F, Jagust WJ. Alzheimer\u2019s disease neuroimaging I. Comparison of visual and quantitative Florbetapir F 18 positron emission tomography analysis in predicting mild cognitive impairment outcomes. JAMA Neurol. 2015;72:1183\u201390.","journal-title":"JAMA Neurol"},{"key":"3591_CR30","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2165\/00003088-200645100-00001","volume":"45","author":"ML Chen","year":"2006","unstructured":"Chen ML. Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2006;45:957\u201364.","journal-title":"Clin Pharmacokinet"},{"key":"3591_CR31","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s12149-015-0957-7","volume":"29","author":"M Senda","year":"2015","unstructured":"Senda M, Yamamoto Y, Sasaki M, Yamane T, Brooks DJ, Farrar G, et al. An exploratory efficacy study of the amyloid imaging agent [(18)F]flutemetamol in Japanese Subjects. Ann Nucl Med. 2015;29:391\u20139.","journal-title":"Ann Nucl Med"},{"key":"3591_CR32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00259-014-2890-8","volume":"42","author":"M Senda","year":"2015","unstructured":"Senda M, Sasaki M, Yamane T, Shimizu K, Patt M, Barthel H, et al. Ethnic comparison of pharmacokinetics of (18)F-florbetaben, a PET tracer for beta-amyloid imaging, in healthy Caucasian and Japanese subjects. Eur J Nucl Med Mol Imaging. 2015;42:89\u201396.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-016-3591-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-016-3591-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-016-3591-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T06:58:26Z","timestamp":1589612306000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-016-3591-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,13]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["3591"],"URL":"https:\/\/doi.org\/10.1007\/s00259-016-3591-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,13]]},"assertion":[{"value":"13 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This work is a part of the Translational Research Promotion Project\/Research Project for the Development of a Systematic Method for the Assessment of Alzheimer\u2019s Disease, sponsored by the New Energy and Industrial Technology Development Organization of Japan. The Japanese Alzheimer\u2019s Disease Neuroimaging Initiative is also supported by a Grant-in-Aid for Comprehensive Research on Dementia from the Japanese Ministry of Health, Labour and Welfare, as well as by the grants from J-ADNI Pharmaceutical Industry Scientific Advisory Board companies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"TN has been an employee of Eli Lilly Japan since February 2016. However, all of his effort in the present study had been done when he was a member of Institute of Biomedical Research and Innovation. K. Ito has received research grants from Nihon Medi-Physics Co., Ltd. and a speaker honorarium from Eli Lilly Japan. MS is a principal investigator of clinical trials sponsored by AVID\/Eli Lilly and GE Healthcare. MS is also an advisor for AVID\/Eli Lilly, GE Healthcare and Piramal Imaging for which fee was paid to the institution.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the each institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from every subject prior to participation and also from caregiver of the subject categorized as AD or MCI.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}